Home Cart Sign in  
Chemical Structure| 36341-25-0 Chemical Structure| 36341-25-0

Structure of YL-109
CAS No.: 36341-25-0

Chemical Structure| 36341-25-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

YL-109 is an anticancer agent with ability to inhibit breast cancer cell growth and invasiveness in vitro and in vivo.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of YL-109

CAS No. :36341-25-0
Formula : C14H11NO2S
M.W : 257.31
SMILES Code : OC1=CC=C(C2=NC3=CC=CC=C3S2)C=C1OC
MDL No. :MFCD00030231
InChI Key :KRVBOHJNAFQFPW-UHFFFAOYSA-N
Pubchem ID :3155228

Safety of YL-109

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Description
YL-109 is an anticancer agent capable of triggering the expression of the carboxyl terminus of Hsp70-interacting protein (CHIP) via activation of the aryl hydrocarbon receptor (AhR) pathway. It can suppress the proliferation and invasiveness of breast cancer cells[1].

In Vitro:

Cell Line
Concentration Treated Time Description References
MDA-MB-231 cells 4.02 µM (IC50) 96 hours YL-109 inhibited MDA-MB-231 cell proliferation in a dose-dependent manner Sci Rep. 2014 Nov 18;4:7095
MCF-7 cells 85.8 nM (IC50) 96 hours YL-109 inhibited MCF-7 cell proliferation in a dose-dependent manner Sci Rep. 2014 Nov 18;4:7095

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c female mice Endometriosis mouse model Intraperitoneal injection 15 mg/kg Twice a week for one month YL-109 significantly suppressed the growth of ectopic endometrium in the endometriosis mouse model, reducing glucose consumption and lactate production. Cell Mol Life Sci. 2022 Dec 19;80(1):13
Nude mice Breast cancer xenograft model Subcutaneous injection 15 mg/kg Every 2 days, tumor growth was monitored YL-109 significantly inhibited tumor growth of MCF-7 and MDA-MB-231 cells and reduced lung metastasis of MDA-MB-231 cells Sci Rep. 2014 Nov 18;4:7095

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.89mL

0.78mL

0.39mL

19.43mL

3.89mL

1.94mL

38.86mL

7.77mL

3.89mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories